Rexgenero Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Increasing popularity of effective medications like beta-blockers, antiplatelet drugs, and statins is expected to drive critical limb ischemia treatment market growth.Wilmington, Delaware, United States, July 24, 2023 (GLOBE NEWSWIRE) -- The global critical limb ischemia treatment market is anticipated to grow at 8.03 % CAGR from 2023 to 2031. A market valuation of US$ 3.49 billion by 2031. The demand for critical limb ischemia therapeutics is expected to rise due to increasing prevalence of hyp

That "Critical Limb Ischemia Treatment Market Forecast to 2028 – Covid-19 Impact and Global Analysis report added to Insight Partners has covered and analyzed

Press release content from Business Wire. The AP news staff was not involved in its creation. Ixaka (formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company January 18, 2021 GMT LONDON--(BUSINESS WIRE)--Jan 18, 2021-- Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The Company’s shareholders have funded the business with over £40 million in financing. Previously Rexgenero Ltd, a UK-based company pioneering the development of cell therapies to treat serious diseases such as cancer and chroni...